The Medical Journal of Australia (MJA) is undergoing a significant transformation in 2026, and it's a story that demands attention. This year marks a pivotal moment in the journal's evolution, with a renewed focus on its future trajectory and a commitment to innovation.
But what does this mean for the journal's identity and its role in the medical community?
The MJA team has been hard at work behind the scenes, re-evaluating their processes and appearance to ensure they remain a leading voice in Australian healthcare research and policy. This journey involves a delicate balance between upholding the journal's values and adapting to the evolving needs of the medical community.
As with any journal, the MJA's priorities are set by its editorial team, reflecting their commitment to publishing high-quality research and commentary that influences health policy and medical practice in Australia. However, the challenge lies in managing this process while maintaining a diverse and inclusive publication range.
Here's where it gets intriguing: the MJA has seen a surge in submissions, with a notable increase in international contributions. In 2025, submissions rose to 1619, with 1087 from Australia and 532 from the rest of the world. This growth presents a unique opportunity, but it also demands a strategic approach to ensure the journal's resources are utilized effectively.
The MJA categorizes submissions into four groups, each with its own implications. The first group includes papers that are irrelevant to Australian healthcare, often due to their non-Australian context or pre-clinical nature. These papers, sometimes identified as products of paper mills, are unlikely to be published, and their processing takes valuable time away from editors and authors alike.
The second group consists of papers that may have some relevance to Australian healthcare but do not meet the MJA's qualitative criteria for high priority. These criteria, outlined in the journal's guidance, emphasize the importance of disease burden, public health interest, Aboriginal and Torres Strait Islander-led research, and immediate impact on clinical practice or policy.
The third group is a tricky one. These papers meet the qualitative criteria but have underlying issues in design or writing that suggest fundamental problems. These issues might include research lacking rigor, ethical concerns, poor reporting, or limited access to data. For non-research manuscripts, a common pitfall is a lack of grounding in previous work.
The fourth group comprises papers that meet the criteria and are well-reported, making them prime candidates for peer review and eventual publication.
And this is the part most people miss: the MJA's strategic planning in 2025 has been instrumental in shaping these processes. The journal has restructured its team, introducing part-time Associate Editors to expand its reach and build editorial capacity. This move aims to make the MJA more selective in its external peer review process, ensuring that reviewers' time is valued and authors receive meaningful feedback.
Additionally, the MJA is streamlining its post-review processes, focusing on pre-acceptance collaboration with authors to minimize post-acceptance edits. This shift will result in faster online publication of accepted papers.
The journal is also revamping its visual identity and publishing cadence. A new PDF format has already been introduced, and articles are now published continuously, with compiled issues appearing monthly. A website redesign is also on the horizon, promising enhanced functionality and display.
These changes are carefully crafted to benefit authors and readers, but feedback is always welcome. As the MJA continues its journey, it invites the medical community to engage in a dialogue about these developments. Are these changes a step in the right direction, or is there room for further improvement? The journal's commitment to quality and innovation remains unwavering, but the conversation is far from over.
